MedPath

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Phase 2
Recruiting
Conditions
Celiac Disease
Interventions
Drug: Placebo
First Posted Date
2025-02-04
Last Posted Date
2025-06-26
Lead Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Target Recruit Count
48
Registration Number
NCT06807463
Locations
🇺🇸

Teva Investigational Site 12133, Marrero, Louisiana, United States

🇺🇸

Teva Investigational Site 12131, Colorado Springs, Colorado, United States

🇺🇸

Teva Investigational Site 12134, Inverness, Florida, United States

and more 9 locations

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older with Asthma

Phase 3
Not yet recruiting
Conditions
Asthma
Interventions
Drug: FP
Drug: ABS
Drug: Placebo
First Posted Date
2025-06-04
Last Posted Date
2025-06-10
Lead Sponsor
Teva Branded Pharmaceutical Products R&D Inc.
Target Recruit Count
555
Registration Number
2024-517991-39-00
Locations
🇵🇱

Synexus Polska Sp. z o.o., Gdansk, Poland

🇵🇱

Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o., Tarnow, Poland

🇵🇱

Santa Sp. z o.o., Lodz, Poland

and more 26 locations

Mass Balance Clinical Trial With TEV-56286

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: [14C]-TEV-56286
First Posted Date
2024-10-04
Last Posted Date
2025-01-29
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
8
Registration Number
NCT06627231
Locations
🇳🇱

Teva Investigational Site 38189, Groningen, Netherlands

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Phase 1
Recruiting
Conditions
Vitiligo
Interventions
First Posted Date
2024-10-03
Last Posted Date
2025-06-05
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
28
Registration Number
NCT06625177
Locations
🇺🇸

Teva Investigational Site 12043, Scottsdale, Arizona, United States

🇺🇸

Teva Investigational Site 12052, Hot Springs, Arkansas, United States

🇺🇸

Teva Investigational Site 12044, Fremont, California, United States

and more 8 locations

A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy

Phase 2
Recruiting
Conditions
Multiple System Atrophy
Interventions
Drug: Placebo
First Posted Date
2024-04-16
Last Posted Date
2025-05-26
Lead Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Target Recruit Count
103
Registration Number
2023-505320-54-00
Locations
🇫🇷

Assistance Publique Hopitaux De Paris, Paris Cedex 13, France

🇫🇷

Centre Hospitalier Universitaire De Bordeaux, Bordeaux, France

🇫🇷

Centre Hospitalier Universitaire De Toulouse, Toulouse, France

and more 25 locations

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-06-28
Last Posted Date
2025-05-15
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
240
Registration Number
NCT06480552
Locations
🇺🇸

Teva Investigational Site 12023, Cincinnati, Ohio, United States

🇺🇸

Teva Investigational Site 12017, Los Angeles, California, United States

🇺🇸

Teva Investigational Site 12021, Lake Mary, Florida, United States

and more 7 locations

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Phase 1
Completed
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
First Posted Date
2024-03-19
Last Posted Date
2025-03-06
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
91
Registration Number
NCT06319170
Locations
🇺🇸

Teva Investigational Site 15730, Los Alamitos, California, United States

🇺🇸

Teva Investigational Site 15727, Hollywood, Florida, United States

🇺🇸

Teva Investigational Site 15729, Atlanta, Georgia, United States

and more 2 locations

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Phase 1
Active, not recruiting
Conditions
Schizophrenia
Interventions
First Posted Date
2024-03-18
Last Posted Date
2025-06-04
Lead Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Target Recruit Count
116
Registration Number
NCT06315283
Locations
🇺🇸

Teva Investigational Site 15739, Los Alamitos, California, United States

🇺🇸

Teva Investigational Site 15740, Torrance, California, United States

🇺🇸

Teva Investigational Site 15738, Hollywood, Florida, United States

and more 6 locations

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: Fp MDPI
First Posted Date
2024-03-04
Last Posted Date
2025-01-10
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
30
Registration Number
NCT06290102
Locations
🇺🇸

Teva Investigational Site 12010, Mobile, Alabama, United States

🇺🇸

Teva Investigational Site 12003, Long Beach, California, United States

🇺🇸

Teva Investigational Site 12007, Miami, Florida, United States

and more 7 locations

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2024-02-12
Last Posted Date
2025-06-22
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
24
Registration Number
NCT06253546
Locations
🇨🇳

Teva Investigational Site 88049, Beijing, China

🇨🇳

Teva Investigational Site 88048, Beijing, China

🇨🇳

Teva Investigational Site 88047, Guangzhou, China

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath